• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    bioAffinity Technologies, Inc. - Common Stock (NQ: BIAF )

    1.430 +0.060 (+4.38%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about bioAffinity Technologies, Inc. - Common Stock

    < Previous 1 2 3 4 5 Next >
    bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
    From bioAffinity Technologies, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer
    From bioAffinity Technologies, Inc.
    Via Business Wire
    Are Pharma Stocks Harmful To Your Financial Health ?
    It seems time for the Securities and Exchange Commission to oversee stock advertising and consider a ban, or at least a danger warning label. 
    Via Talk Markets
    bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
    From bioAffinity Technologies, Inc.
    Via Business Wire
    BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q2 2024
    bioAffinity Technologies just reported results for the second quarter of 2024. 
    Via InvestorPlace
    bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales
    From bioAffinity Technologies, Inc.
    Via Business Wire
    Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
    From bioAffinity Technologies, Inc.
    Via Business Wire
    Crude Oil Falls Sharply; Exxon Mobil Earnings Top Views
    Via Benzinga
    Exposures Fossil Fuels
    Nasdaq Tumbles 3%; US Economy Adds 114,000 Jobs In July
    Via Benzinga
    Topics Economy
    Exposures Economy
    Dow Dips Over 400 Points; Apple Posts Upbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESSWIRE
    bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
    From bioAffinity Technologies, Inc.
    Via Business Wire
    BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESSWIRE
    bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
    From bioAffinity Technologies, Inc.
    Via Business Wire
    BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q1 2024
    bioAffinity Technologies just reported results for the first quarter of 2024. 
    Via InvestorPlace
    bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies News Update
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
    From bioAffinity Technologies, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q4 2023
    bioAffinity Technologies just reported results for the fourth quarter of 2023. 
    Via InvestorPlace
    bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
    From bioAffinity Technologies, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.